Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 364, Issue 6, 2001, Pages 551-557

  Pauli Magnus, Christiane ^a   Rekersbrink, Sabine ^a   Klotz, Ulrich ^a   Fromm, Martin F ^a  

^a DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

Author keywords

Drug interaction; P glycoprotein; Proton pump inhibitors

Indexed keywords

CYCLOSPORIN; DIGOXIN; GLYCOPROTEIN P; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; VALSPODAR;

ANIMAL CELL; ARTICLE; CELL STRAIN; CELL STRAIN CACO 2; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENCY; DRUG TRANSPORT; HUMAN; HUMAN CELL; IC 50; NONHUMAN;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ANIMALS; ANTI-ULCER AGENTS; BENZIMIDAZOLES; BIOLOGICAL TRANSPORT; CACO-2 CELLS; DIGOXIN; DRUG INTERACTIONS; ENZYME INHIBITORS; EPITHELIAL CELLS; HUMANS; LLC-PK1 CELLS; OMEPRAZOLE; P-GLYCOPROTEIN; PROTON PUMPS; SULFOXIDES; SWINE;

EID: 0035214120     PISSN: 00281298     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00210-001-0489-7     Document Type: Article

References (38)

1. Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole
2. Effect of omeprazole treatment on diazepam plasma levels in slow versus normal rapid metabolizers of omeprazole
3. Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells
4. A study of the interaction between omeprazole and cyclosporine in renal transplant patients
5. Transport and epithelial secretion of the cardiac glycoside, digoxin, by human intestinal epithelial (Caco-2) cells
6. Quinidine single dose pharmacokinetics and pharmacodynamics are unaltered by omeprazole
7. Inhibition of P-glycoprotein-mediated drug transport: A unifying mechanism to explain the interaction between digoxin and quinidine
8. Effects of clarithromycin on the metabolism of omeprazole in relation to CYP2C19 genotype status in humans
9. Omeprazole fails to alter the cytochrome P450-dependent 2-hydroxylation of estradiol in male volunteers
10. Pharmaco-dynamics and kinetics of omeprazole MUPS 20 mg and panto-prazole 40 mg during repeated oral administration in Helicobacter pylori-negative subjects
11. Biochemistry of multidrug resistance mediated by the multidrug transporter
12. The interaction of digoxin and rifampin: Role of intestinal P-glycoprotein
13. Effect of omeprazole on concentrations of clarithromycin in plasma and gastric tissue at steady state
14. Lack of interaction between panto-prazole and digoxin at therapeutic doses in man
15. Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability
16. Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo
17. Drug interactions with agents used to treat acid-related diseases
18. Drug absorption limited by P-glycoprotein-mediated secretory drug transport in human intestinal epithelial Caco-2 cell layers
19. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors
20. Pharmacokinetic considerations in the eradication of Helicobacter pylori
21. Rabeprazole: A review of its use in acid-related gastrointestinal disorders
22. Lansoprazole. An update of its pharmacological properties and clinical efficacy in the management of acid-related disorders
23. The mechanism of action of the gastric acid secretion inhibitor omeprazole
24. Interaction of proton pump inhibitors with cyto-chromes P450: Consequences for drug interactions
25. Pharmacokinetic drug interactions with anti-ulcer drugs
26. The effect of oral omeprazole on the disposition of lignocaine
27. Minor effect of multiple dose omeprazole on the pharmacokinetics of digoxin after a single oral dose
28. Absence of the mdr1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A
29. Influence of single- and multiple-dose omeprazole treatment on nifedipine pharmacokinetics and effects in healthy subjects
30. Review article: Comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors
31. Omeprazole does not affect measured CYP3A4 activity using the erythromycin breath test
32. Active secretion of drugs from the small intestinal epithelium in rats by P-glycoprotein functioning as an absorption barrier
33. The interaction of proton pump inhibitors with cytochromes P450
34. Drug interactions with proton pump inhibitors
35. Effect of clarithromycin on renal excretion of digoxin: Interaction with P-glycoprotein
36. P-glycoprotein and cytochrome P-450 3A inhibition: Dissociation of inhibitory potencies
37. Reversal of anti-cancer drug resistance by macrolide antibiotics in vitro and in vivo
38. The digoxin-propafenone interaction: Characterization of a mechanism using renal tubular cell monolayers